Oncolytics Biotech Inc T.ONC

Why others & not Onc ( yet)…?

[canadafan]

Dealing with facts & not conjectures, Onc has the following to offer.
They have strong clinical proof over countless trials of bith efficacy & safety.
Some if the recent juniors bought out, we barely @ phase one trials.
So, pharma cones in early , with in one case $850 million up front & future biobucks on performance.

ONC at its presnt clinical state.
Two phase 3 resdy, with FDA fast track.
The pancreatic cancer for example , showed near 3x existing standard of care results.
That is why CGAR granted Onc $5 million to add an additional arm.
VERY positive factual information P.

accepting that, Onc mangement are mandated to get best value for the company.
Not quickest deal, but the best deal.

To determine that price requires a lot of investigations, being legal, clinical , financial.
All of which requires a lot of time.
The future changed dramatically the last 6-9 months.
Most significant being the rapid progress of the Gobblet trials, results etc.

no deal? Not because of lacking clinical evidence, exact opposite.
moving forward, up to the executives of both sides to come up with a reasonable price for both sides.
keep in mind, the accelerated approval " talk" on Onc publications is only one month old.
FYI, they could of had a deal, back 2014 or so.
would have resulted in 90% dillution, Total loss of control regarding end use of Pela, including closing it down.
That was deemed as unacceptable. Hence the Aware-1, & Bracelet trials.
pharma said, you want a mature product price, show us a mature product trial evidence.
recall the term " derisking"
Both bracelet & aware-1 , proved results 
Both just made public in the very enthusiastic N.R. Early October.
So, while Onc has been around since 1999. The recent results are only a month or so, public.
Brining that to the table is clearly much more than recent deals announced.
i suggest you read the October N.R,
and then cover your short position.

[spesestsemper]

Your a bit misleading in your post 2024-10-04 | Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path | TSX:ONC | Press Release The strong efficacy results from BRACELET-1 provide the foundation for a large Phase 2 study designed to support an accelerated approval.  You state that they

[Noteable]

An adaptive Phase 2 cliniclal trial for a drug that is then granted a FDA  Accelerated Approval as early as when the patient enrollment stage, becomes a confirmatory trial /.post-market approval Phase 4 clinical study  - without any Phase 3 designation necessary. This is especially true for biological drugs which address orphan/ rare diseases with unmet medical treatment needs, which is

[Noteable]

October 04, 2024 -  Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path “Having treated well over 100 HR+/HER2- metastatic breast cancer patients in multiple clinical studies, these results provide the basis for a development path leading to an accelerated approval." https

[Noteable]

" The recently reported final BRACELET-1 study results provide clear evidence of pelareorep’s ability to improve outcomes in patients with advanced breast cancer (link to press release). Patients in the paclitaxel control arm had a median overall survival of 18.2 months. However, more than half of the patients in the pelareorep combination therapy arm were still alive at the time of the final

[13X2413]

Not short. Just p*ssed off. 

[13X2413]

Not short. Just p*ssed off.